Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 106 AL 120

Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide

Mohamed A, Cortez L, de Chaves EP.

Curr Protein Pept Sci. 2011 May;12(3):235-57. doi: 10.2174/138920311795860214.

The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics

Pritchard SM, Dolan PJ, Vitkus A, Johnson GV.

J Cell Mol Med. 2011 Aug;15(8):1621-35. doi: 10.1111/j.1582-4934.2011.01273.x.

The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations

Bonda DJ, Lee HG, Camins A, Pallàs M, Casadesus G, Smith MA, Zhu X.

Lancet Neurol. 2011 Mar;10(3):275-9. doi: 10.1016/S1474-4422(11)70013-8.

[Neuromidin in mixed vascular and Alzheimer's dementia]

Damulin IV, Stepkina DA, Lokshina AB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2):40-3.

Focused ultrasound: crossing barriers to treat Alzheimer's disease

Burgess A, Aubert I, Hynynen K.

Ther Deliv. 2011 Mar;2(3):281-6. doi: 10.4155/tde.11.5.

Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease

Axelsen PH, Komatsu H, Murray IV.

Physiology (Bethesda). 2011 Feb;26(1):54-69. doi: 10.1152/physiol.00024.2010.

[The role of biological sciences in understanding the genesis and a new therapeutic approach to Alzheimer's disease]

Tęgowska E, Wosińska A.

Postepy Hig Med Dosw (Online). 2011 Feb 17;65:73-92. doi: 10.5604/17322693.933430.

PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism

Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M.

J Alzheimers Dis. 2011;25(1):151-62. doi: 10.3233/JAD-2011-101356.

Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity

Tõugu V, Tiiman A, Palumaa P.

Metallomics. 2011 Mar;3(3):250-61. doi: 10.1039/c0mt00073f. Epub 2011 Feb 25.

Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept)

Romberg C, Mattson MP, Mughal MR, Bussey TJ, Saksida LM.

J Neurosci. 2011 Mar 2;31(9):3500-7. doi: 10.1523/JNEUROSCI.5242-10.2011.

When will Alzheimer's disease be cured? A pharmaceutical perspective

Townsend M.

J Alzheimers Dis. 2011;24 Suppl 2:43-52. doi: 10.3233/JAD-2011-110020.

Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology

Morimoto K, Horio J, Satoh H, Sue L, Beach T, Arita S, Tooyama I, Konishi Y.

J Alzheimers Dis. 2011;25(1):59-76. doi: 10.3233/JAD-2011-101815.

Animal models in the drug discovery pipeline for Alzheimer's disease

Van Dam D, De Deyn PP.

Br J Pharmacol. 2011 Oct;164(4):1285-300. doi: 10.1111/j.1476-5381.2011.01299.x.

Hippocampal atrophy rates in Alzheimer's disease: automated segmentation variability analysis

Mouiha A, Duchesne S; Alzheimer's Disease Neuroimaging Initiative.

Neurosci Lett. 2011 May 9;495(1):6-10. doi: 10.1016/j.neulet.2011.02.065. Epub 2011 Mar 1.

Genetics of Alzheimer's disease: new evidences for an old hypothesis?

Lambert JC, Amouyel P.

Curr Opin Genet Dev. 2011 Jun;21(3):295-301. doi: 10.1016/j.gde.2011.02.002. Epub 2011 Mar 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias